Roth Capital Issues Optimistic Estimate for GANX Earnings

Gain Therapeutics, Inc. (NASDAQ:GANX) – Research analysts at Roth Capital increased their Q1 2025 earnings per share (EPS) estimates for Gain Therapeutics in a note issued to investors on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings of ($0.14) per share for the quarter, up from their previous forecast of ($0.17). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.73) EPS and FY2026 earnings at ($1.13) EPS.

A number of other equities research analysts have also weighed in on GANX. Roth Mkm reissued a “buy” rating and set a $7.00 price target on shares of Gain Therapeutics in a report on Tuesday, December 24th. Scotiabank assumed coverage on Gain Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 target price on the stock. Chardan Capital restated a “buy” rating and set a $6.00 price target on shares of Gain Therapeutics in a research note on Friday, March 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Monday, March 17th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Stock Up 4.4 %

Shares of Gain Therapeutics stock opened at $1.89 on Wednesday. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $4.04. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average is $2.20 and its 200 day moving average is $2.07. The company has a market cap of $50.13 million, a price-to-earnings ratio of -1.72 and a beta of 0.14.

Gain Therapeutics (NASDAQ:GANX) last posted its earnings results on Thursday, March 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.07.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in GANX. Sprott Inc. bought a new position in Gain Therapeutics during the 4th quarter valued at about $30,000. Benedict Financial Advisors Inc. purchased a new stake in shares of Gain Therapeutics in the fourth quarter worth approximately $35,000. Bridgeway Capital Management LLC bought a new stake in shares of Gain Therapeutics during the 4th quarter worth approximately $65,000. Northern Trust Corp boosted its holdings in Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after acquiring an additional 39,642 shares during the period. Finally, Marshall Wace LLP purchased a new position in Gain Therapeutics during the 4th quarter valued at $198,000. Institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.